C&L: Vavricka tapped to run Iroko

Iroko Pharmaceuticals has named John Vavricka as president and CEO. He joins Iroko Pharmaceuticals from Novartis Vaccines and Diagnostics where he was the vice president responsible for commercial operations Americas and Europe

Erimos Pharmaceuticals named J. Scott Mohrland, Ph.D. as its new president and CEO. Jeff Khoo, former Erimos CEO, will serve as executive vice chairman on Erimos' board of directors.

Alba Therapeutics has named Jeffrey Church as its CFO.

Molecular Insight CFO Bob Gallahue has resigned the position "to pursue other opportunities." Molecular COO John McCray will fill the role until a new CFO is found.

Alpharma has named Jeffrey S. Campbell executive vice president and CFO. Campbell has served as interim CFO of Alpharma since September 2006.

Boston Life Sciences has appointed Frank Bobe as executive vice president and chief business officer.

Gene Logic announced that Thomas Barnes, Ph.D. has been promoted to senior vice president, discovery.

Herbert B. Slade, MD has filled the newly-created position of chief medical officer and senior vice president of medical affairs for DFB Branded Pharmaceuticals.

Aeris Therapeutics has appointed May Orfali, MD vice president for clinical research and medical affairs.

Burrill & Company today announced that Dr. Ganesh M. Kishore, PhD has joined the firm as managing director.

Ipsen has appointed Sean McKercher to the company's newly established position of vice president of commercial development in North America.

Exelixis has appointed Richard Buller to the newly created position of vice president, translational medicine.

Cryo-Cell announced that Julie Allickson, Ph.D., has been promoted to vice president,laboratory operations, research and development. Rob Doll has been promoted to vice president, corporate marketing, sales and services.

Dr. Anthony Williams has joined Synta as vice president of clinical research and Mary Drummond has joined the company as director of commercial development for oncology.

Vice President Erik Coats, Ph.D. has been made a full partner of Observant. Robert Ramirez, MBA, has joined the firm as a director.

The Medicines Company has named Hiroaki Shigeta to the company's board of directors.

Pro-Pharmaceuticals has nominated S. Colin Neill to its board of directors.

James W. Mier, M.D. has agreed to join Senesco Technology's scientific advisory board.

Anavex Life Sciences announced that Jean Jacques Bourguignon, Ph.D., has joined the company's scientific team and has been appointed a member of the scientific committee.

TargeGen has named Martin Friedlander M.D., Ph.D. to its scientific advisory board.

Viral Genetics has retained Dr. Sam Gulube and Bada Pharasi for its African advisory team as the company continues the development of VGV-1, the company's HIV/AIDS product, in Africa.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.